Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Killugudi Jayaraman

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|May 8, 2018
Indian biotech sector readies for liftoffKillugudi Jayaraman
Nature Medicine|February 8, 2018
A shot at contraception: In India, a nonagenarian renews testing of a birth control vaccineKillugudi Jayaraman
Nature Biotechnology|September 11, 2010
India's Cipla sets sights on Avastin, Herceptin and EnbrelKillugudi Jayaraman
Nature Medicine|April 9, 2010
Failure of Indian whistleblower scheme points to deeper woesKillugudi Jayaraman
Nature Medicine|April 6, 2013
Under scrutiny, India's medical research council faces reviewKillugudi Jayaraman
Nature Biotechnology|April 8, 2016
India's budget windfall for biotech entrepreneursKillugudi Jayaraman
Nature Medicine|April 9, 2010
India moves toward creating a new cadre of rural doctorsKillugudi Jayaraman
Nature Biotechnology|December 5, 2019
Cut-price CAR-T cell therapies top India's biotech agendaKillugudi Jayaraman
Nature Biotechnology|December 10, 2013
Biocon's first-in-class anti-CD6 mAb reaches the marketKillugudi Jayaraman
Nature Biotechnology|January 11, 2013
India flouts patent for blockbuster biologicKillugudi Jayaraman
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|May 8, 2018
Indian biotech sector readies for liftoffKillugudi Jayaraman
Nature Medicine|February 8, 2018
A shot at contraception: In India, a nonagenarian renews testing of a birth control vaccineKillugudi Jayaraman
Nature Biotechnology|September 11, 2010
India's Cipla sets sights on Avastin, Herceptin and EnbrelKillugudi Jayaraman
Nature Medicine|April 9, 2010
Failure of Indian whistleblower scheme points to deeper woesKillugudi Jayaraman
Nature Medicine|April 6, 2013
Under scrutiny, India's medical research council faces reviewKillugudi Jayaraman
Nature Biotechnology|April 8, 2016
India's budget windfall for biotech entrepreneursKillugudi Jayaraman
Nature Medicine|April 9, 2010
India moves toward creating a new cadre of rural doctorsKillugudi Jayaraman
Nature Biotechnology|December 5, 2019
Cut-price CAR-T cell therapies top India's biotech agendaKillugudi Jayaraman
Nature Biotechnology|December 10, 2013
Biocon's first-in-class anti-CD6 mAb reaches the marketKillugudi Jayaraman
Nature Biotechnology|January 11, 2013
India flouts patent for blockbuster biologicKillugudi Jayaraman
Pageof 3